Is BioDelivery Sciences International, Inc. (BDSI) A Good Stock To Buy?

Seeing as BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has experienced falling interest from the entirety of the hedge funds we track, we can see that there exists a select few hedge funds that decided to sell off their entire stakes heading into Q4. At the top of the heap, Phill Gross and Robert Atchinson’s Adage Capital Management sold off the biggest stake of the 700 funds watched by Insider Monkey, valued at an estimated $6.4 million in stock. Cliff Asness’s fund, AQR Capital Management, also dumped its stock, about $1 million worth. These bearish behaviors are important to note, as total hedge fund interest dropped by 1 funds heading into Q4.

Let’s go over hedge fund activity in other stocks – not necessarily in the same industry as BioDelivery Sciences International, Inc. (NASDAQ:BDSI) but similarly valued. These stocks are Seabridge Gold, Inc. (USA) (NYSE:SA), National Research Corp (NASDAQ:NRCIA), Luxfer Holdings PLC (ADR) (NYSE:LXFR), and Threshold Pharmaceuticals, Inc. (NASDAQ:THLD). All of these stocks’ market caps are closest to BDSI’s market cap.

As you can see these stocks had an average of 8.25 hedge funds with bullish positions and the average amount invested in these stocks was $35 million. That figure was $70 million in BDSI’s case. Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) is the most popular stock in this table. On the other hand National Research Corp (NASDAQ:NRCIA) is the least popular one with only 5 bullish hedge fund positions. Compared to these stocks BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.